¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º *Tc lc u  
=D;n#n7  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ = sZ58xA  
! =Scpo_  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) Z<D8{&AjS  
9Xl[AVs:M  
1. ICAM-1 jRiXN %  
Yo%ph%e  
2. interleukin 12(IL-12) qofD@\-  
MHj RPh  
3. tumor infiltrating lymphocyte :'`y}'  
G+7#!y Y  
4. TCR/CD3 complex HTz5LAe~b7  
H^ 'As;R  
5. hematopoietin receptor family ) _n=it$  
~Uw;6VXV1  
6. individual idiotype(IdI) 7+9o<j@@o  
'VgEf:BS  
7. integrin ,I6li7V  
7F2 WmMS  
8. colony-stimulatory factor (CSF) ~+ kfb^<-  
"7q!u,u  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ui RO,B}z  
ZJe^MnE (G  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? {8I,uQO  
@r&*Qsf|   
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ j"hNkCF  
|yl,7m/B-G  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠAl1_\vx7  
e@Mg9VwDc  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ cO$xT;kK  
oN2#Jh%dH  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) J}NMF#w/;  
>?O?U=:<  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ STl8h}C  
L{&>,ww  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) ~x7CI  
Mw3$QRM  
3. immunoglobulin superfamily (IgSF) k%3)J"|/  
Pbd[gKX_  
4. selectin r+8)<Xt+p  
#+QJ5VI :  
5. anti-idiotypic antibody (¦ÁId) jzJQ/ZFS  
b@c(Nv  
6. major histocompatibility complex(MHC) E[WU  
JH| D  
7. immunotolerance i=L 86Ks  
X::@2{-@y  
8. biological reponse modifier(BRM) ?N<,;~  
^vxx]Hji  
9. immune reponse gene (Ir gene) F!3p )?  
ber&!9  
10. reshaped antibody (or reconstituted antibody) X~UL$S;  
X1d{7H8A2  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© w[F})u]E  
O}%E SAB  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ +.&P$`;TZj  
l9C `:g  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? CuK>1_Dq  
Zr1"'+-  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ g4=C]\1  
Ux1j+}y  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? qSlo)aP  
+_ /ys!  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ KB^8Z@(+  
m_Pk$Vwx  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? 1TX3/]:  
[<5/s$,i  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ p7 !y#  
 [Rub  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ +L"F]_?  
+'SL5d*  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? NC!B-3?x  
0C.5Qx   
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ RhKDQGdd  
2q]ZI  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: [T4{K &  
Xp| 4WM  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: 7FkiT  
50|nQ:u,  
ÃâÒßѧ |=v,^uo  
n:B){'S  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© g33Y$Xdk  
I L7kpH+y  
1. CD8 Xs|d#WbX  
9{U@s  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) rXz q :  
>r C*.  
3. immunoglobulin fold(Ig fold) 88<d<)7t  
{>vgtkJ  
4. cadherin (Ca-dependent cell adhesion moleculers) F'>yBDm*OM  
RhmkpboucC  
5. idiotype-anti-idiotypic antibody immune network theory o3\^9-jmp  
y{<js!au  
6. HLA class II antigen nC !NZ  
!-n* ]C  
7. complementarity-determining region (CDR) W`u @{Vb]  
<&`Rf6  
8. perforin(or pore-forming protein ,PFP) ~N}Zr$D  
cZ !$XXA`  
9. high affinity IL-2 receptor 'LuxF1>  
=`>e i  
10. artificial active immunization jj;TS%  
"x.iD,>k  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Het >G{  
<\uDtbK  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ_*g .U=u  
9bRUN<  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6{udNv X  
IO7gq+  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ S76MY&Vx23  
g,o46`6"  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ N}[!QE  
= =Q*|L-g  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ Z  eY *5m  
?G7*^y&Q  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? eHGx00:  
">h$(WCK  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ `'P&={p8  
U6wy^!_X9  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ H/Ql  
B<Cg_C  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ [euR<i*I#  
I`jG  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ %qE"A6j  
VK,{Mu=.9  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 9M1DE  
Wlq3r#  
1. immunoglobulin gene rearrangement _\,lv \u  
<tsexsw  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) Z 5P4 H  
{(asy}a9K  
3. flow cytometry(FCM) ieWXr4@:  
BG.8 q4[  
4. carrier effect 2ve<1+V_  
#)48dW!n  
5. positive selection of T lymphocytes in thymus L *|P'  
=(P$P   
6. mouse TH1(Th1) and TH2(Th2) subsets & @_PY  
 xI#rnx*  
7. perforin (pore-forming protein ,PFP) (Jj xrZ+L  
QuI!`/N)z  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) ^'Rs`e  
7i02M~*uS  
9. SH-2(src-homology region 2) '"LaaTTs  
d1t_o2  
10. Ab2¦Â (internal image) Lc]hwMGR*  
N:#$S$  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© (G$Q\>  
iYw1{U  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? QR~4Fe  
,VUOsNN4\  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? YD9vWk \/  
=JP Y{'VO  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ{9j0k`A  
yzL9Ic  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ v6! `H  
I4UsDs*BD  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠg1y@z8Z{  
4R8Qn^  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) H+gB|  
\)aFYDq#\  
ÃâÒßѧרҵ£º jJ2{g> P0P  
OH]45bd &7  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ ZdPqU \G^q  
f8f3[O!x  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 1E4`&?  
S?D]P'<  
´«È¾²¡Ñ§×¨Òµ£º V;)+v#4{  
XMxm2-%olP  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ 3Y +;8ld  
YT)1_>*\  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ b%C7 kL-  
J5Q.v;  
Ïû»¯×¨Òµ£º .;,,{ ;  
KMl3`+i  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ &=T>($3r94  
=t~]@?]1D  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 5RY-.c4}  
pMAFZfte!x  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ @.G;dL.f{  
3fYfj  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© #0^a-47PA<  
$0~1;@`rQ6  
1. Fas(CD95)/FasL ir|L@Jj,  
oIE3`\xS  
2. common chain of cytokine receptor b`;&o^7gMO  
e%9zY{ABR%  
3 . TCR/CD3 complex y^ st T^  
e%7#e%1s  
4. negaive selection of thymocytes 3?!c<^"e  
$o)}@TC  
5. artificial active immune usi3z9P>n  
Wk }}f|O0  
6. anti-idiotypic ^7*zi_Q  
{817Svp@  
7. IgSF [l~G7u.d  
_ZK*p+u%  
8. Integrin .GCJA`0h  
|h.@Xy  
9. chemokine \@{TF((Y  
YlZ&4   
10. B7/CD28 xd4~[n\hm  
+Je%8jH  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© .W\x{h  
yy`XtJBWWs  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ m:9|5W  
/%b nG(4  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ "=2'Oqp1  
zXId up@  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ YQR[0Y&e=  
bUuQ"!>ppu  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ |[ )pQGw  
M'pIAm1p  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ Y3H5}4QD  
sH%Ts@Pl  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ }V 4u`=  
zNg[%{mz  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© l.BiE<&  
/^WOrMR  
1. B7/CD28 w8`B}Dr23  
UMK9[Iy$<M  
2. Th1 subset )OK"H^}f  
_SMi`ie#  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© fk\]wFj  
WwxV} ?Cf+  
4. antibody affinity maturation ^E".`~R  
@h/-P'Lc=7  
5. AP-1 dt/-0~U  
(#]9{ C;  
6. single chain variable fragment£¨ScFv£© h\+8eeIl  
;s+3 #Py  
7. NK cell receptor e2L>"/  
_`,ZI{.J^  
8. Zinkernagel-Doherty phenomenon 4E+8kz'  
gu&W:FY  
9. Ig fold Qv J29  
?A-f_0<0  
10. CD40/CD40L **.23<n^W  
E%a&6W  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© }' Ph^ %ox  
cg9*+]rc  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ ^oNcZK>  
t3=K>Y@w  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ !/X>k{  
n(C M)(ozU  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ FtlJ3fB@  
D}U gC\u  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ ;vn0b"Fi3  
XEN-V-Z%*  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ MM( ,D& Z  
(!Xb8rV0_  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ ezri9\Ju  
0wAB;|~*62  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ 9fO E .  
5r d t  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© Ds{bYK_y  
2X(2O':Uc  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© 7e D` is  
D&]xKx  
1.Co-stimulators (or co-stimulating molecules) qL w^Qxo  
,'sDauFn  
2.NK-kB x@:98P  
`m$,8f%j6_  
3.Immunoglobulin superfamily S&;)F|-q  
:_+U[k(#  
4.antigen-presenting cell (APC) -w'g0/fD  
>)mF'w  
5.death domain `V.tqZF  
T8x/&g''  
6.CCR and CXCR 9<"F3 F0|  
c)q=il7ef  
7.Lectin (or mitogen) vq@"y%C4  
@(."[O:  
8.Clusters of differentiation, CD) !A14\  
[~;wCW,1  
9.B7 family w[G-=>;  
`];ne]xM  
10.Cytotoxic T lymphocyte, CTL) 7dlMDHp\Y  
=CL,+  
11.IL-15 and IL-15 receptor (IL-15R) jT;'T$  
':utU1dL  
12.MHC restriction QqXaXx;  
e`5:46k|  
13.Affinity-chromatography K5(T7S  
[u-=<hnoa  
14.Cyctosprin A, CsA `2xt%kC  
Aiqb*v$  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) *6v5JH&K  
{4%ddJn[.)  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 9  I&[6}  
-{yG+1  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 #O'g*]j  
Zh?n;n}  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ y!j>_m){w  
V0gu0+u~R  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ rj<-sfs  
-BsZw. 7P  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Zj nWbnW  
ork{a.1-_w  
ÃâÒßѧרҵ£º t"6u  
HZ\= NDz  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ \/r]Ra  
F< ,"{L  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ .GW)"`HbU  
@$wfE\_L  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ Fk?KR  
ck8Qs08  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) zG&yu0;D6  
a$ G hb]  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) ZXWm?9uw  
I>>X-}  
1. ADCC(antibody dependent cell-mediated cytotoxicity) e#?rK=C?9  
C7Hgzc|U  
2. »·æß¾úËØ(cyclosporin) 1qwJPM  
ab<7jfFIa  
3. KIR(killer cell inhibitory receptor) (HeIO  
CWnRRZ}r  
4. HLDA(human leucocyte differentiation antigen) r / L   
U[!wu]HMF  
5. Interleukin 18(IL-18) g^:7mG6C  
t%Y}JKLR  
6. ÕûºÏËØ(integrin) QST-!`]v  
iP?=5j=4  
7. Fas/FasL $H7T|`WI.,  
1.j;Xo/+:V  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) $yMNdBI[  
NW?h~2  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) cX48?srG  
Il<ezD{  
10. Th1/Th2 l' a<k"  
HQ3kxOT  
11. »ùÒòÒßÃç(DNAÒßÃç) $C6O<A  
`"j_]  
12. chemokines and chemokine receptor i>@"&  
 xXZ {  
13. ÃâÒßÄÍÊÜ 7vK}aOs0  
JA^Y:@ <{/  
14. ¹²´Ì¼¤·Ö×Ó `T$CUlt6  
hjY)W;  
15. ËÀÍö½á¹¹Óò(death domain) A(qy>x-BI  
~ny4Ay$#  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) P 4jg]g  
'B$qq[l]S  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 8{ J{)gF  
Ptv=Bwg  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ+"2IQme5  
twJ)h :!_y  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î qUF}rl S=r  
j`kw2 (  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ D<*#. >  
S,TK;g  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå uWKc .  
RzLbPSTQ  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ 2kU=9W6ND  
,V2,FoJ 9  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 5//.q;z  
X(Zo uyD<  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ _4jRUsvjY  
bC@9 */i  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ ?1u2P$d  
-h< Rby  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»